Decision to fine Leadiant for excessive price of CDCA drug
After an investigation ACM has determined that manufacturer Leadiant abused its dominant position by charging an excessive price for its prescription drug. CDCA-Leadiant. This occurred in the period from June 2017 through December 2019. For this violation ACM has imposed a fine on Leadiant of 19,569,500 euros.
Here you can find the summary of the decision. The public version of the full decision will be published at a later date.
Documents
We do our utmost to make our documents accessible.
However, this is unfortunately not always possible.
If you are unable to read a document on our website using a screen reader or if you are unable to discern the colors of charts,
please send us an email.
We will contact you within a week.
And we will try to send you an accessible version within 4 weeks.